Navigation Links
Watson Confirms AVODART(R) Patent Challenge
Date:6/20/2011

PARSIPPANY, N.J., June 20, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dutasteride Capsules, 0.5 mg.  Watson's Dutasteride Capsules product is a generic version of GlaxoSmithKline's AVODART(R), which is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.

GlaxoSmithKline LLC filed suit against Watson on June 17, 2011 in the United States District Court for the District of Delaware seeking to prevent Watson from commercializing its Dutasteride Capsules product prior to the expiration of U.S. Patent No. 5,565,467. GlaxoSmithKline's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until November 17, 2013 or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

For the twelve months ending April 30, 2011, AVODART had total U.S. sales of approximately $580 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.  

AVODART(R) is a registered trademark of GlaxoSmithKline LLC.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:
Investors:
Patty Eisenhaur
(862) 261-8141
Media:
Charlie Mayr
(862) 261-8030


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms Court Decision Rejecting Tevas Motion to Prevent Launch of Generic SEASONIQUE®
2. Watsons Nabumetone Tablets Receive FDA Approval
3. Watson Confirms Pataday™ Patent Challenge
4. Watson Confirms Viagra® Patent Challenge
5. Watson to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
6. Watson Launches Generic AMRIX®
7. Watson Launches Generic Concerta®
8. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
9. Watson First Quarter 2011 Net Revenue Increases to $877 Million
10. New Life Agency Adds Watson to Join Walgreens on The Fertility Pharmacy Care Card for Fertility Medication
11. Watson Confirms Welchol® Patent Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
(Date:5/25/2016)...  Zymo Research Corp. announced today the final ... that help researchers obtain the most accurate and ... rapid growth of the study of microbiomes has ... methods to improve the reproducibility and quality of ... every step of the measurement process including collection ...
(Date:5/25/2016)... 2016  Granger Diagnostics today announced immediate availability of ... infections. This test ensures discovery of ALL bacteria, ... test requires only a simple swab of the wound ... G. Bostwick , MD, Chief Medical Officer, described ... "We are excited to make available, for the ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For Heroes ... lives in military battle for the country. The nonprofit Hope For Heroes partnered ... programs that empower independence for disabled military veterans, as well as police, firemen, and ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is a common ... long-term patient survival, reports a team of UPMC researchers in the largest study ... Journal of Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead ...
(Date:5/26/2016)... ... 2016 , ... MadgeTech will be showcasing its line of data logging ... at the MadgeTech headquarters. With products sold in more than 100 countries around the ... NASA. , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data ...
(Date:5/26/2016)... NY (PRWEB) , ... May 26, 2016 , ... ... Hereditary Retinal Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June ... to the public. , Dr. Maisel, founder of Retina Group of New ...
(Date:5/26/2016)... ... May 26, 2016 , ... In an effort to provide hair restoration information to the ... users and those who do not use the app. Dr. Mohebi, the founder of Parsa ... Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to the Snapchat ...
Breaking Medicine News(10 mins):